These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20003335)

  • 1. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
    Petty RD; Samuel LM; Murray GI; MacDonald G; O'Kelly T; Loudon M; Binnie N; Aly E; McKinlay A; Wang W; Gilbert F; Semple S; Collie-Duguid ES
    BMC Cancer; 2009 Dec; 9():434. PubMed ID: 20003335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer.
    Tan WL; Bhattacharya B; Loh M; Balasubramanian I; Akram M; Dong D; Wong L; Thakkar B; Salto-Tellez M; Soo RA; Fichtner I; Iacopetta B; Soong R
    Cancer Biol Ther; 2011 Mar; 11(6):599-608. PubMed ID: 21378502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
    Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
    Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo studies on the association of long non‑coding RNAs H19 and urothelial cancer associated 1 with the susceptibility to 5‑fluorouracil in rectal cancer.
    Yokoyama Y; Sakatani T; Wada R; Ishino K; Kudo M; Koizumi M; Yamada T; Yoshida H; Naito Z
    Int J Oncol; 2019 Dec; 55(6):1361-1371. PubMed ID: 31638183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy.
    Phua LC; Mal M; Koh PK; Cheah PY; Chan EC; Ho HK
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):817-23. PubMed ID: 23271323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms.
    Plasencia C; Rooney PH; Taron M; Martinez-Balibrea E; McLeod HL; Abad A
    Int J Oncol; 2003 May; 22(5):945-53. PubMed ID: 12684658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
    Wong NA; Brett L; Stewart M; Leitch A; Longley DB; Dunlop MG; Johnston PG; Lessells AM; Jodrell DI
    Br J Cancer; 2001 Dec; 85(12):1937-43. PubMed ID: 11747337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer.
    Garza-Treviño EN; Martínez-Rodríguez HG; Delgado-González P; Solís-Coronado O; Ortíz-Lopez R; Soto-Domínguez A; Treviño VM; Padilla-Rivas GR; Islas-Cisneros JF; Quiroz-Reyes AG; Said-Fernández SL
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
    Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
    Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.
    Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Rogowski W; Domagala W
    Pathol Oncol Res; 2016 Jul; 22(3):601-8. PubMed ID: 26831819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
    Chang W; Gao X; Han Y; Du Y; Liu Q; Wang L; Tan X; Zhang Q; Liu Y; Zhu Y; Yu Y; Fan X; Zhang H; Zhou W; Wang J; Fu C; Cao G
    Gut; 2014 Sep; 63(9):1457-67. PubMed ID: 24173294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Transcriptomic Biomarkers of 5-Fluorouracil Resistance.
    Fekete JT; Győrffy B
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
    Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
    Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
    Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.
    Kumar SS; Tomita Y; Wrin J; Bruhn M; Swalling A; Mohammed M; Price TJ; Hardingham JE
    Clin Transl Oncol; 2017 Jun; 19(6):718-726. PubMed ID: 28005260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Hatch AJ; Sibley AB; Starr MD; Brady JC; Jiang C; Jia J; Bowers DL; Pang H; Owzar K; Niedzwiecki D; Innocenti F; Venook AP; Hurwitz HI; Nixon AB;
    Cancer Med; 2016 Sep; 5(9):2249-60. PubMed ID: 27465221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.